Depletion of PRMT5 inhibits cell proliferation, clonogenic capacity of the cells, and improves the prognosis of cancer patients making PRMT5 an important target for cancer therapy (Pal et al, 2004; Scoumanne et al, 2009; Wei et al, 2012; Chung et al, 2013; Morettin et al, 2015; Yang et al, 2016; Banasavadi-Siddegowda et al, 2018; Saloura et al, 2018; Xiao et al, 2019). The gene discussed is PRMT5; the disease is cancer.